Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transfusion transmitted non-A, non-B hepatitis.

S Iwarson1

  • 1Department of Infectious Diseases, University of Gothenburg, Ostra Sjukhuset, Sweden.

Acta Anaesthesiologica Scandinavica. Supplementum
|January 1, 1988
PubMed
Summary

Non-A, non-B hepatitis (NANBH) is a post-transfusion complication with mild symptoms, often indicated by elevated alanine transferase. This hepatitis can lead to chronic liver disease and cirrhosis in a significant percentage of patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subtypes of Hepatitis B Antigen in Blood Donors and Post-transfusion Hepatitis: Clinical and Epidemiological Aspects.

British medical journal·2010
Same author

Hepatitis A booster vaccination: is there a need?

Lancet (London, England)·2003
Same author

[Exciting progress in the field of infection medicine. Several breakthroughs are to be expected during the next decade].

Lakartidningen·1999
Same author

[New and re-emergent epidemics in the changing surrounding world].

Lakartidningen·1999
Same author

Studies on a Hib-tetanus toxoid conjugate vaccine: effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine.

Vaccine·1999
Same author

[Electronic version of the Fass is also considered to be reliable].

Lakartidningen·1999

Area of Science:

  • Hepatology
  • Transfusion Medicine
  • Virology

Background:

  • Non-A, non-B hepatitis (NANBH) is a significant concern following blood transfusions and blood product administration.
  • The causative agent(s) for NANBH remain unidentified, presenting diagnostic challenges.
  • Symptoms of NANBH are typically mild, with elevated serum alanine transferase levels being the primary indicator of infection.

Purpose of the Study:

  • To investigate the incidence and implications of posttransfusion Non-A, non-B hepatitis (NANBH).
  • To highlight the potential progression of NANBH to chronic hepatitis and cirrhosis.

Main Methods:

  • Comparative analysis of NANBH incidence rates in the US and Sweden.
  • Estimation of NANBH carrier rates among blood donors.
  • Longitudinal observation of NANBH patient outcomes.

Main Results:

  • Posttransfusion NANBH incidence varies globally, with higher rates reported in the US (4-12%) compared to Sweden (average 2%).
  • An estimated 2-3% of Swedish blood donors may be carriers of the NANBH agent.
  • A substantial proportion of patients with posttransfusion NANBH (40-60%) develop chronic hepatitis, with 15-20% progressing to cirrhosis.

Conclusions:

  • Posttransfusion NANBH represents a notable risk, with significant long-term sequelae including chronic hepatitis and cirrhosis.
  • The prevalence of NANBH carriers among blood donors underscores the need for continued vigilance and research into causative agents.
  • Discrepancies in incidence rates between countries suggest potential differences in risk factors or diagnostic practices.

Related Experiment Videos